Michela Pierini

Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma

Agnieszka E. Zając, Piotr Rutkowski, Anna Szumera-Ciećkiewicz, Jakub Piątkowski et autres

Chondrosarcoma (ChS) is a rare bone malignancy with heterogeneous behavior, the molecular and immunological background of which remains unknown. No effective systemic treatment for advanced ChS patients is available. The aim of this study was to develop an immune–mutational classification of ChS …

pl, hu, it, us, fr (code pays fourni par la source)

Psychosocial impact of COVID-19 pandemic on patients with solid malignancies and bone metastases (PsyCO-B): a multicentre prospective observational study

Paolo Taurisano, Ester Cornacchia, Maria Fara De Caro, Vittorio Fusco et autres

Background: COVID-19 pandemic dramatically changed our daily habits. Patients with cancer, particularly those with bone metastases (BM), were among the most concerned individuals, due to both their clinical condition and social distancing. Objectives: This study aimed to explore psychosocial effects of the …

it (code pays fourni par la source)

224eP Systemic mitochondrial alterations in patients with advanced non-small lung cancer revealed by [18F]F-AraG PET imaging

Jelena Levi, Uttam M. Shrestha, Millie Snigdha Das, Minal Vasanawala et autres

us (code pays fourni par la source)

Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials

Emanuela Palmerini, Cristina Meazza, Angela Tamburini, Catalina Márquez-Vega et autres

PURPOSE Outcome of patients with localized osteosarcoma is challenging. The role of mifamurtide is still a matter of debate. Two prospective trials were carried out in Italy (ISG/OS-2) and Spain (GEIS-33) with mifamurtide in ABCB1/P-glycoprotein (Pgp)–positive patients. PATIENTS AND METHODS Patients age …

us, it, es (code pays fourni par la source)

Malignant giant cell tumor of bone: A case series in the denosumab era.

Emanuela Palmerini, Rodrigo A. Vásquez, Alberto Righi, Elisa Carretta et autres

e23510 Background: Giant cell tumor of bone (GCTB) is a locally recurrent, rarely metastasizing tumor. However, GCTB can undergo malignant transformation. Malignancy in GCTB (mGCTB) may be primary (adjacent to a non-malignant GCTB, at first diagnosis) or secondary (after a GCTB recurrence). …

it, cl (code pays fourni par la source)

1774P Immunological-molecular profiling of chondrosarcoma (ChS)

P. Rutkowski, Agnieszka E. Zając, Anna Szumera‐Ciećkiewicz, Jakub Piątkowski et autres

pl, it, fr, hu (code pays fourni par la source)

1969P Intratumoral immune infiltrates in chondrosarcoma (ChS)

Piotr Lukasz Rutkowski, Anna Szumera‐Ciećkiewicz, Agnieszka E. Zając, J. Tuziak et autres

pl, it, fr (code pays fourni par la source)

A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl)

Emanuela Palmerini, Marco Gambarotti, Antoîne Italiano, Michael Jason Nathenson et autres

it, fr, us, gb, es, ch (code pays fourni par la source)

Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study

Emanuela Palmerini, Laura Pazzaglia, Luca Cevolani, Loredana Pratelli et autres

Background: Giant cell tumors of bone (GCTB) are osteolytic tumors. Denosumab, a RANK-L inhibitor, is approved for GCTB. Data on serum bone turnover marker (sBTM) changes are lacking. We present a phase II correlative study on sBTMs in GCTB patients treated with …

it (code pays fourni par la source)

A Global CollaboRAtive Study of CIC-Rearranged, BCOR::CCNB3-Rearranged and Other Ultra-Rare Unclassified Undifferentiated Round Cell Sarcomas (GRACefUl)

Emanuela Palmerini, Marco Gambarotti, Antoîne Italiano, Michael Jason Nathenson et autres

it, fr, nl, us, gb, es, my, ch (code pays fourni par la source)

Metastatic osteosarcoma at diagnosis: Analysis of 92 cases from a single institution.

Alessandra Longhi, Valquiria Broll, Alberto Righi, Antonio Carella et autres

e23506 Background: Metastatic osteosarcoma (MOS) with synchronous metastases accounts for 20-25% of all new cases of osteosarcoma. Lungs are the most common site of metastases at presentation (80%) followed by Bone (10%). 5- years Overall Survival (OS) of MOS ranges from 11 …

it (code pays fourni par la source)

Ostenonecrosis of the jaw (ONJ) after denosumab in patients with giant cell tumor of bone (GCTB): a single institution analysis of a prospective, international study 20062004

Emanuela Palmerini, Elisa Carretta, Alberto Bazzocchi, Marilena Cesari et autres

Background Giant cell tumor of bone (GCTB) is a progressive osteolytic tumor with proven response to denosumab when unresectable or at high surgical risk. We report on incidence of suspected (sONJ) and adjucated (aONJ) osteonecrosis of the jaw cases, from a single …

it (code pays fourni par la source)